Founded in 2014 to address the significant unmet medical needs in China, Zai Lab is a patient-oriented biotechnology research company, dedicated to the development and delivery of best-in-class and first-in-class medicines for “oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in greater China and around the world.”
“We are doing everything in our power to get science out of the lab and into more lives with precision and persistence, never compromising on ethics or quality.”[1]
- Dr. Samantha Du, Founder, CEO & Chairperson of Zai Lab
In recent years China has become one of the most dynamic R&D hubs for innovative medicines across the world. Zai Lab has partnered with leading global biopharmaceutical companies, generating a broad pipeline of innovative late-stage drug candidates, four of which have now been launched in China. The company has quickly become a partner of choice for global companies seeking access to the Chinese market.
Paving a Path to Global Growth
Zai Lab’s longer-term goal is to become a leading global biopharmaceutical company, leveraging its China-based competencies and resources to provide healthcare products to patients around the world. The company is now a fully integrated biopharmaceutical company with four marketed products in China and a growing pipeline with several programs that have global rights.
The global team based in China and the United States has extensive experience working at the highest levels of the biopharmaceutical industry and its expert development team is currently managing more than 50 clinical trials. The commercial success of the company’s product portfolio enables them to further expand their product range to continue treating an increasing number of patients around the world.
Environmental, social and governance innovation
Zai Lab prides itself on being built right from the start and committing from day one to be a responsible corporate citizen. The company recognizes that embracing a strong Environmental, Social and Governance (ESG) philosophy “is not only the right thing to do but also good business practice.”
The company’s ESG strategy, called “Trust for Life,” is being incorporated into all aspects of their business. This includes three focus areas: improving human health, creating better outcomes and acting right now to help create a healthier planet with healthier people.
As a women-founded and led business, the company places extra importance on equity in the workplace. The company’s last ESG report shows that 57% of the workforce are women, and of those women 53.8% hold managerial titles. In a previously male dominated sector this is a monumental step forward in the world of biotechnology equality.
“We want to lay the groundwork for future businesses to see what it's like to be a sustainable company and design it from the start. We realise, though, that sustainability is a continuous journey.”
- Jim Massey, Chief Sustainability Officer at Zai Lab
